Epitomee Medical (Tase: EPIT) developed a breakthrough weight management product based on the use of a device in a capsule that is swallowed by the user daily inducing safe and effective weight loss. Epitomee’s ground-breaking platform technology is based on self-expanding hydro-gel scaffolds produced from biocompatible components and folded into a standard pharmaceutical orally administered capsule. In 2020 the company signed a strategic collaboration agreement with Nestlé Health Science to globally commercialize and distribute Epitomee’s weigh management products. Epitomee’s technology platform enables the creation of swallowable medical devices that can be directed to various targets along the GI tract. In addition to the clinically proven, CE approved weight loss product the company is developing a drug delivery technology aimed at controlled delivery of biologics using oral administration to act along the GI tract achieving therapeutic outcomes in highly prevalent diseases.